KCM
YARW

Kennedy Capital Management’s Yarrow Bioscience YARW Stock Holding History

Kennedy Capital Management’s Portfolio YARW Stock Details YARW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11,415
Closed -$942K – 616
2025
Q2 		$942K Buy
+11,415
New +$742K 0.02% 514

Other funds holding YARW

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Kennedy Capital Management's YARW Position: Q3 2025 in Review

Kennedy Capital Management sold out of Yarrow Bioscience (YARW) in Q3 2025, closing a stake of 11,415 shares — an estimated $942K sold.

Kennedy Capital Management first reported a position in YARW in Q2 2025 and held it in 1 quarter. The position peaked at $942K in Q2 2025. 34 funds tracked by Wall St. Rank hold YARW as of Q3 2025.

  • Kennedy Capital Management reported no remaining Yarrow Bioscience position as of Q3 2025 after selling out during the quarter.
  • Kennedy Capital Management sold 11,415 Yarrow Bioscience shares in Q3 2025, an estimated $942K.
  • Kennedy Capital Management first reported a position in Yarrow Bioscience in Q2 2025 and held it in 1 quarter.
  • Kennedy Capital Management's Yarrow Bioscience position peaked at $942K in Q2 2025.
  • 34 funds tracked by Wall St. Rank held Yarrow Bioscience as of Q3 2025.

Based on Kennedy Capital Management's 13F filing for Q3 2025, filed 13 Nov 2025.